USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research

Zacks Research upgraded shares of USANA Health Sciences (NYSE:USNA) from a strong sell rating to a hold rating in a report issued on Monday morning,Zacks.com reports.

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Down 8.2%

USNA opened at $18.97 on Monday. The business’s fifty day simple moving average is $20.68 and its 200 day simple moving average is $23.60. USANA Health Sciences has a 52 week low of $18.48 and a 52 week high of $38.32. The stock has a market cap of $346.77 million, a PE ratio of 34.49, a P/E/G ratio of 0.94 and a beta of 0.67.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. The firm had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million. USANA Health Sciences had a return on equity of 6.76% and a net margin of 1.16%. As a group, equities analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On USANA Health Sciences

Several institutional investors have recently added to or reduced their stakes in USNA. Pzena Investment Management LLC increased its position in shares of USANA Health Sciences by 1.2% in the third quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after acquiring an additional 14,328 shares during the period. Renaissance Technologies LLC grew its stake in shares of USANA Health Sciences by 1.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock worth $22,522,000 after purchasing an additional 21,793 shares during the last quarter. Vanguard Group Inc. increased its holdings in USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after purchasing an additional 57,249 shares during the period. Dimensional Fund Advisors LP raised its position in USANA Health Sciences by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after purchasing an additional 17,318 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences in the 4th quarter worth approximately $11,485,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Key USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Q4 EPS beat consensus and revenue came in essentially in line; management posted $0.60 EPS vs. estimates of $0.41 and revenue of $226.2M vs. ~$225.96M, showing the company can still deliver upside on profitability. Read More.
• Positive Sentiment: Management set a 2026 sales growth target of ~4% and emphasized omnichannel expansion and product innovation — a constructive strategic outlook that can support medium-term revenue recovery. Read More.
• Positive Sentiment: An analyst upgrade from Zacks (strong sell → hold) reduces immediate sell-side pressure and may limit downside if execution improves. Read More.
• Neutral Sentiment: Full earnings call / transcripts were published; they contain management commentary on customer metrics and channel mix that investors will parse for signs of sustainable recovery. Read More.
• Negative Sentiment: Despite the beat, the quarter showed customer count declines and “mixed” underlying demand — a key driver of today’s weakness as investors worry growth will be slow to return. Read More.
• Negative Sentiment: The market reaction (elevated volume and shares trading below recent moving averages) reflects concern that beat was small and near-term momentum is weak — analysts and traders are focusing on customer trends and margin sustainability. Read More.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.